Background {#Sec1}
==========

Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) receptor, are quickly becoming a staple in our arsenal of anti-cancer agents. PD-1 signaling normally inactivates effector T cells when bound to its ligands PD-L1 and PD-L2; thus, inhibition of this pathway reinvigorates T cell antitumor responses \[[@CR1]\]. Nivolumab and pembrolizumab are monoclonal antibodies that block PD-1 and have demonstrated substantial benefit in melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and numerous other cancers \[[@CR2]\].

Although inhibitors of PD-1 provide significant therapeutic benefit, many immune-related adverse events (irAEs) have emerged with these therapies. The most common irAEs include dermatologic toxicities and thyroid dysfunction \[[@CR3]--[@CR5]\]. Other clinically significant toxicities include colitis, hypophysitis, pneumonitis, and hepatitis \[[@CR4]--[@CR7]\]. These events arise from dysregulation of self-tolerance that is normally mediated by PD-1/PD-L1 interactions \[[@CR8]\]. Additionally, anti-PD-1 (specifically nivolumab) may be combined with ipilimumab, an antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4), which when bound to costimulatory molecules on antigen-presenting cells inactivates T cells. Ipilimumab works synergistically with anti-PD-1 agents and improves antitumor efficacy but also increases the frequency and severity of irAEs \[[@CR3], [@CR5]\].

Recently, cases of hematologic irAEs were reported with anti-PD-1 therapy, specifically autoimmune hemolytic anemia and immune thrombocytopenic purpura (ITP) \[[@CR9]--[@CR12]\]. Although cases of thrombocytopenia induced by either pembrolizumab or ipilimumab alone have been reported, its incidence, spectrum of severity, and development of ITP have not been established \[[@CR13], [@CR14]\]. Given the rapid rise of immunomodulatory therapy use in numerous cancers, there is a clear need to identify and characterize these hematologic irAEs. Here, we report two cases of severe ITP resulting from checkpoint inhibitor therapy and the largest multi-institutional case series of thrombocytopenia induced by checkpoint inhibitor therapy.

Case presentations {#Sec2}
==================

A 47-year-old patient presented in 2011 with stage IIb melanoma on her left forearm, which was removed by wide local excision with a concurrent negative sentinel lymph node biopsy. Four years later, she presented with recurrent metastatic melanoma with a *BRAF* ^V600M^ mutation. She initially responded to combination BRAF and MEK inhibition but developed progressive disease within five months. Two weeks later, she received her first infusion of combination ipilimumab and nivolumab. She developed bleeding from mucosal areas and petechiae fifteen days following her first dose of combination checkpoint inhibitor therapy with severe thrombocytopenia (PLT \< 5000/uL) and an elevated immature platelet fraction of 15.4% (0.9 to 7.0% normal range). She had no history of autoimmune or coagulation disorders, and the remainder of her laboratory evaluation was unrevealing. She was presumed to have new-onset ITP and was started on methylprednisolone and intravenous immunoglobulin (IVIG) (Fig. [1](#Fig1){ref-type="fig"}). After five days of steroids and IVIG without significant improvement in her platelet count, a bone marrow biopsy revealed a hypercellular marrow with increased megakaryocytes (Fig. [2](#Fig2){ref-type="fig"}), further supporting the diagnosis of ITP. Her treatment was escalated to weekly rituximab with addition of a single dose of romiplostim, a thrombopoietin analog. Seven days after steroids and IVIG, and two days after rituximab, her platelet counts began to improve, reaching normal range (137,000 to 397,000/uL) by one week, and she subsequently did not require additional platelet transfusions (Fig. [1](#Fig1){ref-type="fig"}). Between her second and third infusion of rituximab, she transiently relapsed to a platelet count of 54,000/uL. She received a total of four doses of rituximab in accordance with standard therapy for ITP. Eight days after her last dose, she was rechallenged with nivolumab monotherapy and subsequently experienced a partial response with no relapse of her ITP.Fig. 1Checkpoint inhibitor-induced ITP refractory to glucocorticoids subsequently responds to second-line treatment Fig. 2Bone marrow from patient with checkpoint inhibitor-induced ITP before rituximab treatment. H&E stained section of the bone marrow biopsy, 100 × magnification. The bone marrow is moderately hypercellular for age with trilineage hematopoiesis and increased megakaryocytes (*black arrows*) with a range of morphologies and mild clustering. These findings, coupled with the patient's peripheral thrombocytopenia and elevated IPF, are compatible with a diagnosis of ITP

A second patient, a 45-year-old female with a BRAF wild-type melanoma, received nivolumab as neoadjuvant therapy in a clinical trial and became thrombocytopenic (49,000/uL) 43 days later. She was asymptomatic and was treated with prednisone for three weeks, with elevation of platelet levels to baseline (307,000/uL). However, thrombocytopenia recurred with a platelet nadir of 28,000/uL, and she required an additional 12-week steroid taper before her platelets recovered. She later developed metastatic disease to the brain and underwent resection of a large frontal lesion, as well as gamma knife irradiation to several smaller lesions. Due to limited treatment options, she was administered ipilimumab monotherapy, eight months after receiving nivolumab. Within eight days, her platelet count decreased from 75,000 to 8000/uL, and two days later, she developed hemorrhage in her intracranial metastasis with no detectable platelets. Her ITP ultimately resolved after treatment with prednisone, IVIG, and rituximab and discontinuation of ipilimumab.

To assess the incidence and clinical patterns of thrombocytopenia, including potential cases of ITP, following immune checkpoint inhibition, we performed retrospective reviews of electronic medical records at Georgetown Lombardi Cancer Center, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, MD Anderson Cancer Center, and Vanderbilt-Ingram Cancer Center. Patients with melanoma were included if they experienced thrombocytopenia following treatment with a checkpoint inhibitor that was clinically diagnosed as ITP or was not attributable to another cause. The project was approved by IRBs of respective institutions with waiver of consent. Statistical analysis was performed using R version 3.3.0.

We assessed the frequency of thrombocytopenia induced by treatment with checkpoint inhibitors across these five institutions and identified 11 cases, several presumed to be ITP based on clinical diagnostic criteria. A total of 2360 patients with melanoma receiving checkpoint inhibitor therapy were reviewed, suggesting an incidence of well under 1%. These patients were Caucasian men (58%) or women (42%) with melanoma; none had a previous diagnosis of ITP or a history of thrombocytopenia prior to initiation of treatment. Various checkpoint inhibitor regimens were represented (Table [1](#Tab1){ref-type="table"}). The average time to onset of checkpoint inhibitor-induced thrombocytopenia was 70 days (range, 12 to 173 days), and the average platelet count was 61,000/uL (range, \<5000 to 104,000/uL) with an average decrease of 70% from baseline (range, 38 to 99%). No significant differences were found among the varying checkpoint inhibitor regimens.Table 1Patients with thrombocytopenia and/or confirmed new-onset ITP following checkpoint inhibitor therapy for melanomaCase 1Case 2Case 3Case 4Case 5Case 6Case 7Case 8Case 9Case 10Case 11Age, years/sex52/F80/M55/F44/M67/M45/F53/M48/F36/F56/M69/MCheckpoint inhibitor(s) and dosage(s)Ipi (3 mg/kg) +\
nivo (1 mg/kg)Pembro\
(2 mg/kg)Ipi (3 mg/kg) + nivo\
(1 mg/kg)Ipi\
(3 mg/kg)Ipi (3 mg/kg) + nivo\
(1 mg/kg)Nivo\
(3 mg/kg)Pembro\
(2 mg/kg)Pembro\
(2 mg/kg)Pembro\
(2 mg/kg)Nivo\
(3 mg/kg)Nivo\
(3 mg/kg)Best response to therapyPRPRPRPDN/APDN/ASDPDSDN/ATime to TP onset, days1521506268431217340130151Other irAEsNoneNeurologicalEndocrine, skinGINeurological, liverNoneNeurological, liverSkinNoneNoneNoneCounts at TP onsetWBC, 10^3^/uL\
HCT, %\
PLT, 10^3^/uL15.4\
34\
Less than 55.8\
43.5\
1047\
37.8\
6112.8\
N/A\
183.8\
35.8\
866\
40.7\
493.7\
35.3\
5311.9\
31.3\
898.1\
28.2\
584.9\
41\
734\
28.5\
74% PLT decrease from baseline99%38%80%91%40%84%69%53%74%N/A75%Signs and symptoms of TPHematochezia, petechiae, gingival bleeding, epistaxisNoneNoneEpistaxisBleeding from tumorNoneNoneNoneNoneNoneNoneConfirmation of ITPBone marrow biopsy---Peripheral smear------------------------Treatment 1/highest PLTMePRDL + IVIG/18None requiredNone requiredPrednisolone + IVIG/30Prednisone/118Prednisone/307None requiredNone requiredNone requiredNone requiredNone requiredTreatment 2/highest PLTRituximab + prednisone/364------None requiredNone required^a^Prednisone/269---------------Entries with "---" indicate not applicable to patient*Ipi* ipilimumab, *Nivo* nivolumab, *Pembro* pembrolizumab, *PR* partial response, *PD* progression of disease, *SD* stable disease, *N/A* not available, *TP* thrombocytopenia, *GI* gastrointestinal, *irAEs* immune-related adverse events, *WBC* white blood count, *HCT* hematocrit, *PLT* platelet, *MePRDL* methylprednisolone, *IVIG* intravenous immunoglobulin^a^Patient relapsed after initial steroid treatment

Of the 11 patients, four required immunosuppressive treatment with corticosteroids, and two of those cases were refractory to steroids. A higher percentage of patients treated with ipilimumab (single agent or combined with nivolumab) required immunosuppressive treatment (75%, 3 of 4) compared to those treated with anti-PD-1 monotherapy (14%, 1 of 7). The majority of patients displayed no clinical signs or symptoms of thrombocytopenia and required no therapies with spontaneous resolution (Table [1](#Tab1){ref-type="table"}). Our first case described in detail above had the most severe episode of thrombocytopenia with confirmed ITP by bone marrow biopsy.

Conclusions {#Sec3}
===========

Thrombocytopenia, especially ITP, induced by immune checkpoint inhibitors appears to be a relatively uncommon irAE that is manageable with standard treatment algorithms. In our series, the majority of patients had mild thrombocytopenia that resolved spontaneously or responded to standard corticosteroid regimens. However, in two severe cases, steroids, IVIG, and rituximab were administered with ultimate recovery. In the first case, nivolumab monotherapy was resumed with excellent tolerance. On the other hand, the second patient relapsed with subsequent immune checkpoint inhibition.

Primary ITP is a disorder caused by the formation of autoantibodies targeting platelet antigens, leading to thrombocytopenia \[[@CR15]\]. ITP is a diagnosis of exclusion and may be challenging given the lack of specific testing and a wide differential diagnosis. ITP is thought to occur after an inciting event activates or alters the immune system, such as an infection, hematopoietic malignancy, or pharmacologic immune checkpoint inhibition \[[@CR16]\]. However, most cases are idiopathic in etiology. A majority of acute cases (50--90%) are responsive to standard corticosteroid and IVIG therapy, though a fraction of cases require second-line treatment, usually involving a combination of rituximab and a thrombopoietin agonist \[[@CR17]\]. In mouse models, there is loss of peripheral self-tolerance through alteration of immune homeostasis and evidence of regulatory T cell (Treg) deficiency associated with ITP \[[@CR18]\]. Comparison of bone marrow between patients with ITP and normal donors revealed that those with ITP have lower levels of Tregs and abnormal levels of Th1 and Th17 cells \[[@CR16]\]. Recent work demonstrated that patients with chronic ITP exhibit lower levels of PD-1 expression in total peripheral blood samples, compared with healthy controls \[[@CR19], [@CR20]\]. A single case report showed that a patient who developed nivolumab-induced ITP had higher PD-1 expression on B cells \[[@CR11]\].

Our experience suggests that thrombocytopenia, including ITP, may rarely complicate immune checkpoint inhibitor therapy but is usually mild and can resolve spontaneously or with standard treatment algorithms. The onset of ITP varies substantially, though a majority occurs within the first 12 weeks after initiation of checkpoint inhibition, consistent with other irAEs \[[@CR21]--[@CR23]\]. Although our observations on checkpoint inhibitor rechallenge after resolution of ITP are limited, our experience suggests that increased clinical vigilance should be used, especially with ipilimumab.
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